Accounts Payable and Accrued Expenses |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2022 | ||||||||||||||||||||||||||||||||||||||||||||||
Payables and Accruals [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||
Accounts Payable and Accrued Expenses | 7. Accounts Payable and Accrued Expenses: Accounts payable and accrued expenses consist of the following (in thousands):
The net decrease in accrued salaries and incentive compensation of $138.6 million, from December 31, 2021 to March 31, 2022, is primarily due to the payment of performance-based incentive compensation, principally to the Company’s affiliated physicians, partially offset by performance-based incentive compensation accrued during the three months ended March 31, 2022. A majority of the Company’s payments for performance-based incentive compensation is paid annually during the first quarter. |